ALEC

Alector Inc. (ALEC) | Rumor.io

Alector

ALEC

Attention (50-day avg)0%

Attention rank (50-day avg)#3,917

Bullish sentiment (50-day avg)100%

Price to earnings ratio-1.39

Market capitalization214.4M

Earnings per share-1.09

Dividend yield (TTM)—

Revenue (annual)21M

Net income (annual)-142.9M

Social

What share of all stock conversation is about ALEC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Oct 22

Alector's (ALEC) dementia drug, latozinemab, failed to slow patient decline in a late-stage trial, leading to a 60% share price drop and the discontinuation of the program.
The company will cut approximately 49% of its staff and refocus on Alzheimer's and blood-brain-barrier delivery platforms.
Multiple firms, including BTIG Research, William Blair, and Cantor Fitzgerald, have downgraded Alector's stock, citing the failed trial and the company's shift in focus.

Generated by AI

Sentiment

Of the messages about ALEC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	37.44% -37.18
Bearish	—	—	0% 0	62.56% +37.18

Bullish· Jul 6

Alector, Inc. (ALEC) has a strong buy volume, indicating a bullish sentiment.
The company's recent deal with GSK has led to a significant pullback, making it a good opportunity for long-term investors.
Alector's stock price is expected to continue rising, with some analysts predicting it may never pull back again, driven by strong demand and the need for shorts to cover their positions.

Bearish· Jul 29

The stock's price drop may be attributed to a "sell off" in the biotech sector, rather than the company's specific results.
The disconnect between the company's value and its cash reserves may persist, making it a challenging investment opportunity.
The stock's reaction may be an overreaction to the news, with some investors expecting "bad news" or an insufficiently positive outcome.

Generated by AI

Topics

Of the messages about ALEC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	44.39%
Analysts	—	—	—	26.46%
Controversies	—	—	—	0.9%
Earnings	—	—	—	10.31%
Macro	—	—	—	0%
Technical Analysis	—	—	—	17.94%

Analysts· Mar 4

Analysts at BofA/Merrill initiated coverage of Alector ($ALEC) with a Buy rating and a $26 price target.
Analysts at Barclays initiated coverage of Alector ($ALEC) with an Overweight rating and a $27 price target.
Analysts at Morgan Stanley initiated coverage of Alector ($ALEC) with an Overweight rating and a $27 price target.

Announcements· Sep 12

Alector (ALEC) has initiated a Phase 1 clinical trial of AL044 for the treatment of Alzheimer's disease.
The trial aims to evaluate the safety and efficacy of AL044 in patients with Alzheimer's disease.
Alector has announced the initiation of this clinical trial, marking a significant step in the development of AL044 as a potential treatment for Alzheimer's disease.

Generated by AI

Community

Of the messages about ALEC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	13.64%	32.69%
Newcomers	100%	100%	86.36%	67.31%

Regulars· Oct 22

Alector's dementia drug, latozinemab, failed to slow patient decline in a late-stage trial, leading to the discontinuation of the trial's open-label extension and a 49% workforce reduction.
The biotech will focus on Alzheimer's and blood-brain-barrier delivery platforms, and Alector shares have tumbled 60% after the Phase 3 trial failed to show clinical benefit in frontotemporal dementia patients.
Alector has been downgraded by multiple firms, including Mizuho, BTIG, Cantor Fitzgerald, and Cowen, citing the failure of the latozinemab trial and a reduced price target for the company.

Newcomers· Oct 22

Alector's phase 3 trial for latozinemab in frontotemporal dementia due to a GRN mutation has top-line results, but the outcome is uncertain.
The company is cutting 49% of staff and restructuring amid the failure of its latozinemab program, which was partnered with GSK.
Alector's stock is experiencing unusual volume, with an unusually high ratio of current to average volume, potentially indicating increased investor interest or activity.

Generated by AI

News

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York)Thursday, September 10, 2026, at 2:10 p.m. ET, fireside chat Morgan Stanley 24th Annual Global Healthcare Conference (N

26d agoYahoo! Finance Canada

Also Discussed

Investors talking about ALEC also mention

#	Name	Attention
1	Denali Therapeutics Inc.DNLI	0%new
2	Annexon Inc.ANNX	0%+0
3	NextCure, Inc.NXTC	0%0
4	Legend Biotech Corporation ADRLEGN	0%+0
5	Regenxbio Inc.RGNX	0%+0
6	BCEL - Atreca, Inc.	——
7	INmune Bio Inc.INMB	0%0
8	Arcus Biosciences, Inc.RCUS	0%new
9	YMAB - Y-mAbs Therapeutics, Inc.	——
10	Precision BioSciences, Inc.DTIL	0%new

Alector Inc.

Healthcare
Biotechnology

Alector Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. Alector Inc. applies its immuno-neurology platform to target the immune dysfunction and protein-related pathology associated with conditions such as Alzheimer’s disease, Parkinson’s disease, and frontotemporal dementia. The company’s current portfolio includes monoclonal antibody and other biologic programs designed to restore healthy immune function in the brain, supported by biomarker-guided clinical development. It also advances Alector Brain Carrier, a proprietary blood-brain barrier platform intended to improve therapeutic delivery to the central nervous system. Headquartered in South San Francisco, California, Alector Inc. operates as a research-driven biopharmaceutical company with a focus on translating genetics, immunology, and neuroscience into treatments for severe brain disorders.

Website

Location

131 Oyster Point Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about ALEC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Oct 22

Alector's (ALEC) dementia drug, latozinemab, failed to slow patient decline in a late-stage trial, leading to a 60% share price drop and the discontinuation of the program.
The company will cut approximately 49% of its staff and refocus on Alzheimer's and blood-brain-barrier delivery platforms.
Multiple firms, including BTIG Research, William Blair, and Cantor Fitzgerald, have downgraded Alector's stock, citing the failed trial and the company's shift in focus.

Generated by AI

Sentiment

Of the messages about ALEC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	37.44% -37.18
Bearish	—	—	0% 0	62.56% +37.18

Bullish· Jul 6

Alector, Inc. (ALEC) has a strong buy volume, indicating a bullish sentiment.
The company's recent deal with GSK has led to a significant pullback, making it a good opportunity for long-term investors.
Alector's stock price is expected to continue rising, with some analysts predicting it may never pull back again, driven by strong demand and the need for shorts to cover their positions.

Bearish· Jul 29

The stock's price drop may be attributed to a "sell off" in the biotech sector, rather than the company's specific results.
The disconnect between the company's value and its cash reserves may persist, making it a challenging investment opportunity.
The stock's reaction may be an overreaction to the news, with some investors expecting "bad news" or an insufficiently positive outcome.

Generated by AI

Topics

Of the messages about ALEC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	44.39%
Analysts	—	—	—	26.46%
Controversies	—	—	—	0.9%
Earnings	—	—	—	10.31%
Macro	—	—	—	0%
Technical Analysis	—	—	—	17.94%

Analysts· Mar 4

Analysts at BofA/Merrill initiated coverage of Alector ($ALEC) with a Buy rating and a $26 price target.
Analysts at Barclays initiated coverage of Alector ($ALEC) with an Overweight rating and a $27 price target.
Analysts at Morgan Stanley initiated coverage of Alector ($ALEC) with an Overweight rating and a $27 price target.

Announcements· Sep 12

Alector (ALEC) has initiated a Phase 1 clinical trial of AL044 for the treatment of Alzheimer's disease.
The trial aims to evaluate the safety and efficacy of AL044 in patients with Alzheimer's disease.
Alector has announced the initiation of this clinical trial, marking a significant step in the development of AL044 as a potential treatment for Alzheimer's disease.

Generated by AI

Community

Of the messages about ALEC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	13.64%	32.69%
Newcomers	100%	100%	86.36%	67.31%

Regulars· Oct 22

Alector's dementia drug, latozinemab, failed to slow patient decline in a late-stage trial, leading to the discontinuation of the trial's open-label extension and a 49% workforce reduction.
The biotech will focus on Alzheimer's and blood-brain-barrier delivery platforms, and Alector shares have tumbled 60% after the Phase 3 trial failed to show clinical benefit in frontotemporal dementia patients.
Alector has been downgraded by multiple firms, including Mizuho, BTIG, Cantor Fitzgerald, and Cowen, citing the failure of the latozinemab trial and a reduced price target for the company.

Newcomers· Oct 22

Alector's phase 3 trial for latozinemab in frontotemporal dementia due to a GRN mutation has top-line results, but the outcome is uncertain.
The company is cutting 49% of staff and restructuring amid the failure of its latozinemab program, which was partnered with GSK.
Alector's stock is experiencing unusual volume, with an unusually high ratio of current to average volume, potentially indicating increased investor interest or activity.

Generated by AI

Alector

Social

Oct 22

Bullish· Jul 6

Bearish· Jul 29

Analysts· Mar 4

Announcements· Sep 12

Regulars· Oct 22

Newcomers· Oct 22

Alector at Morgan Stanley conference: reset centers on brain delivery

Alector at Cantor healthcare conference: brain-shuttle pipeline in focus

Alector’s Grace Wong-Sarad sells $24,665 in shares

Alector CEO Arnon Rosenthal sells $193,473 in stock

Alector CFO Neil Berkley sells $77,948 of ALEC shares

Alector to Participate in Upcoming Healthcare Conferences

Also Discussed

Alector Inc.

Company Information

Location

Alector at Morgan Stanley conference: reset centers on brain delivery

Alector at Cantor healthcare conference: brain-shuttle pipeline in focus

Alector’s Grace Wong-Sarad sells $24,665 in shares

Alector CEO Arnon Rosenthal sells $193,473 in stock

Alector CFO Neil Berkley sells $77,948 of ALEC shares

Alector to Participate in Upcoming Healthcare Conferences

Also Discussed

Social

Oct 22

Bullish· Jul 6

Bearish· Jul 29

Analysts· Mar 4

Announcements· Sep 12

Regulars· Oct 22

Newcomers· Oct 22